Have £5,000 to invest? I’d buy these 2 FTSE 100 growth stocks

These FTSE 100 growth stocks are beating the market. Roland Head explains why he expects these big-cap winners to deliver further gains.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The FTSE 100 is often associated with huge, mature businesses that pay dividends but deliver very little growth. Today I want to get away from that cliché and look at two terrific growth stocks that have made it into the blue-chip index.

Both of my picks have delivered double-digit share price gains over the last two years — the FTSE 100 has fallen by around 15% over the same period.

Growth stock #1: a pharma play

Hikma Pharmaceuticals (LSE: HIK) has been a top performer so far this year, rising by around 20% in five months. Although pharmaceutical firms have benefited from extra investor interest due to the coronavirus pandemic, I believe Hikma is a genuine growth stock, with solid profits and good prospects.

The group’s business is centred around producing injectable medicines and generic versions of branded products that have lost their patent protection. It’s a very profitable business, with an operating margin of 24% in 2019.

Cash generation is also strong and unlike some larger pharma groups, Hikma doesn’t rely on borrowed cash. Net debt was just $242m at the end of 2019, giving a leverage multiple of just 0.4x EBITDA. In plain English, that’s very low.

Why I’d buy

City forecasts suggest that Hikma’s profits will rise by around 8% this year, with a 10% increase pencilled in for 2021.

The firm’s shares are currently trading close to all-time highs, leaving them with a 2020 forecast price/earnings ratio of around 18. That may not seem cheap, but it’s actually well below the UK pharmaceutical sector average P/E of 30.

Profits are expected to rise by a further 10% in 2021. I see the firm as a growth stock to buy at current levels.

Growth stock #2: my bet on UK property

The UK housing market might not seem like the safest investment at the moment. But I think my next pick is an essential service that estate agents can’t live without — even in a downturn.

Property listing website Rightmove (LSE: RMV) dominates the UK market, leaving rivals Zoopla and OnTheMarket.com trailing in the distance. According to the firm, it had a market share of over 75% in 2019, based on the time spent browsing the top four UK property websites.

This dominance gives Rightmove a lot of pricing power. The company generated an operating profit of £214m on revenue of £289m last year. That’s equivalent to a profit margin of 74%. It’s not hard to see why this has been such a successful growth stock — the Rightmove share price has risen by nearly 40% over the last 18 months.

A long-term winner?

Estate agents tend to complain about Rightmove’s pricing. Some big estate agency groups even clubbed together to launch a rival, OnTheMarket.com.

I have some sympathy with the estate agents’ complaints. But Rightmove is expanding steadily into the letting sector and now also lists new homes. In reality, I believe this website will continue to be an essential part of most estate agents’ businesses.

Rightmove has cut its fees by 75% for the period from April to July this year. 2020 profits will be down. But analysts expect earnings to bounce back next year — a view I share.

The latest forecasts put Rightmove stock on a price/earnings ratio of 30 for 2021. For such a dominant and profitable business, I think this could be a good buy.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head has no position in any of the shares mentioned. The Motley Fool UK has recommended Hikma Pharmaceuticals and Rightmove. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young woman holding up three fingers
Investing Articles

Just released: our 3 top income-focused stocks to buy before December [PREMIUM PICKS]

Our goal here is to highlight some of our past recommendations that we think are of particular interest today, due…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Up 125% in 5 years, the BAE share price has beaten Rolls-Royce. Which is better?

Both the BAE and Rolls-Royce share prices have been having a storming time. Here's how they stack up against each…

Read more »

Investing Articles

With P/E ratios of 7.2 and 9, I think these FTSE 100 shares are bargains!

The FTSE 100 has risen sharply in 2024, but there are still lots of top value shares out there. Royston…

Read more »

Investing Articles

This skyrocketing US growth stock has put all others to shame — including its core investment!

Up 378% this year, the spectacular growth of this US tech stock is leaving all others in the dust. But…

Read more »

Investing Articles

I’d buy this FTSE dividend share to target a lifelong second income

Our writer thinks investing in dividend stocks from the UK stock market is the best way for him to generate…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing For Beginners

The Barclays share price keeps surging! Was I wrong to sell the stock?

Jon Smith explains why the Barclays share price is still rising, even though he feels that further gains could be…

Read more »

Investing Articles

1 stock set to gatecrash the FTSE 100 in 2025!

Our writer considers a quality stock that's poised to join the FTSE 100 next year. Could there also be a…

Read more »

Businesswoman calculating finances in an office
Investing Articles

As earnings growth boosts the Imperial Brands share price, is it a top FTSE 100 dividend choice?

The Imperial Brands share price has come storming back as investors piled in for the big dividends. What's next, after…

Read more »